That is my thinking as well. The Phase 2b trial with over 300 participants (not 30) went very well, and moving to 900 in Phase 3 with a nearly identical protocol is, mathematically speaking, almost a sure thing mathematically speaking to see a reproduction of the Phase 2b results in Phase 3. So, the risk sits outside of mathematical predictions
As many here have mentioned, there are no sure bets in Phase 3 trials, but I am at a loss as to what the high-IQ analysts internally at the big pharma could be imagining. Or perhaps OPT has rejected their multibillion-dollar advances.
Certainly, I'm thinking of big buy if OPT's stock gets into the 40s.
Interesting speculation that a low stock price may force OPT's hand into accepting a bad deal as the possibility of a CR is diminished.
- Forums
- ASX - By Stock
- Ann: Opthea Completes Enrollment in Phase 3 Clinical Program
That is my thinking as well. The Phase 2b trial with over 300...
-
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
43.0¢ |
Change
0.020(4.88%) |
Mkt cap ! $529.3M |
Open | High | Low | Value | Volume |
41.5¢ | 43.5¢ | 40.3¢ | $838.5K | 2.001M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 18064 | 43.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
43.5¢ | 29017 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 18064 | 0.430 |
6 | 126967 | 0.425 |
3 | 26073 | 0.420 |
5 | 141609 | 0.415 |
5 | 48539 | 0.410 |
Price($) | Vol. | No. |
---|---|---|
0.435 | 29017 | 1 |
0.440 | 67248 | 4 |
0.445 | 32248 | 2 |
0.450 | 60000 | 1 |
0.455 | 53936 | 1 |
Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |